Skip to main content
رجوع
VCYT logo

Veracyte, Inc.

جودة البيانات: 100%
VCYT
NASDAQ Healthcare Biotechnology
KWD 33.54
▲ KWD 1.70 (5.34%)
القيمة السوقية: 2.67B
نطاق اليوم
KWD 32.08 KWD 33.81
نطاق 52 أسبوعًا
KWD 22.61 KWD 50.71
حجم التداول
1,235,624
متوسط 50 يوم / 200 يوم
KWD 37.13 / KWD 34.68
الإغلاق السابق
KWD 31.84

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E 40.2 0.4
P/B 2.0 2.9
ROE % 5.3 3.8
Net Margin % 12.8 3.9
Rev Growth 5Y % 23.9 10.0
D/E 0.0 0.2

السعر المستهدف للمحللين

Hold
KWD 44.500 +32.7%
Low: KWD 37.000 High: KWD 50.000
مكرر الربحية المستقبلي
20.2
ربحية السهم المستقبلية
KWD 1.661
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
580 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 2.130
KWD 2.091 – KWD 2.162
850 M 1
FY2029 KWD 2.027
KWD 1.989 – KWD 2.057
780 M 1
FY2028 KWD 1.903
KWD 1.581 – KWD 2.143
710 M 3

النقاط الرئيسية

Revenue grew 23.89% annually over 5 years — strong growth
Earnings grew 174.89% over the past year
Debt/Equity of 0.03 — conservative balance sheet
Generating 126.63M in free cash flow
P/E of 40.16 — premium valuation
PEG of 0.31 suggests growth is underpriced

النمو

Revenue Growth (5Y)
23.89%
Revenue (1Y)16.01%
Earnings (1Y)174.89%
FCF Growth (3Y)92.25%

الجودة

Return on Equity
5.34%
ROIC4.12%
Net Margin12.83%
Op. Margin14.34%

الأمان

Debt / Equity
0.03
Current Ratio8.15
Interest Coverage0.00

التقييم

P/E Ratio
40.16
P/B Ratio2.04
EV/EBITDA31.59
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 16.01% Revenue Growth (3Y) 19.68%
Earnings Growth (1Y) 174.89% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 23.89% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 517.15M Net Income (TTM) 66.35M
ROE 5.34% ROA 4.72%
Gross Margin 69.62% Operating Margin 14.34%
Net Margin 12.83% Free Cash Flow (TTM) 126.63M
ROIC 4.12% FCF Growth (3Y) 92.25%
Safety
Debt / Equity 0.03 Current Ratio 8.15
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio 40.16 P/B Ratio 2.04
P/S Ratio 5.15 PEG Ratio 0.31
EV/EBITDA 31.59 Dividend Yield 0.00%
Market Cap 2.67B Enterprise Value 2.34B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 517.15M 445.76M 361.05M 296.54M 219.51M
Net Income 66.35M 24.14M -74.40M -36.56M -75.56M
EPS (Diluted) 0.82 0.31 -1.02 -0.51 -1.11
Gross Profit 360.05M 298.15M 248.15M 194.95M 145.11M
Operating Income 74.15M 16.14M -85.80M -41.08M -81.90M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.41B 1.30B 1.11B 1.16B 1.19B
Total Liabilities 96.44M 124.07M 70.80M 81.22M 91.31M
Shareholders' Equity 1.31B 1.18B 1.04B 1.08B 1.10B
Total Debt 39.65M 50.74M 12.63M 14.72M 18.85M
Cash & Equivalents 362.58M 239.09M 216.45M 154.25M 173.20M
Current Assets 488.38M 372.27M 285.62M 248.64M 243.10M
Current Liabilities 59.94M 78.63M 61.24M 62.61M 64.15M

درجات الاستراتيجيات

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#829 of 1024
29

النشاط الأخير

دخل Cash Flow Compounder
Mar 24, 2026